Loading...
OKYO Pharma Limited
OKYO.L•LSE
Healthcare
Biotechnology
£1.40
£-0.45(-24.32%)
OKYO Pharma Limited (OKYO.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for OKYO Pharma Limited (OKYO.L), featuring income statements, balance sheets, and cash flow data.
Revenue Growth
0.00%
Operating Income Growth
99.88%
↑ 99.88%
Net Income Growth
99.87%
↑ 99.87%
Operating Cash Flow Growth
-23.33%
↓ 23.33%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-135.60%
↓ 135.60%
ROIC
-210.95%
↓ 210.95%
OKYO Pharma Limited (OKYO.L) Income Statement & Financial Overview
Analyze OKYO Pharma Limited’s OKYO.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2024 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $0.00 | $101869.00 | $101869.00 | $101869.00 |
| SG&A Expenses | $0.00 | $98006.00 | $98006.00 | $98006.00 |
| Operating Expenses | $0.00 | $199875.00 | $199875.00 | $199875.00 |
| Total Costs & Expenses | $0.00 | $301745.00 | $301745.00 | $301745.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $228.00 | $228.00 | $228.00 |
| Depreciation & Amortization | $0.00 | $1176.00 | $42.00 | $42.00 |
| EBITDA | $0.00 | -$317193.00 | -$317193.00 | -$317193.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | -$301745.00 | -$301745.00 | -$301745.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $0.00 | -$16851.00 | -$16851.00 | -$16851.00 |
| Income Before Tax | $0.00 | -$318596.00 | -$318596.00 | -$318596.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | -$15000.00 | -$15000.00 | -$15000.00 |
| Net Income | $0.00 | -$303596.00 | -$303596.00 | -$303596.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | $0.00 | -$0.001 | -$0.001 | -$0.001 |
| Diluted EPS | $0.00 | -$0.001 | -$0.001 | -$0.001 |
| Weighted Avg Shares Outstanding | $0.00 | $513.90M | $513.90M | $513.90M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $513.90M | $513.90M | $513.90M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan